WideCells Group PLC Grant of Options (2109V)
January 26 2017 - 4:30AM
UK Regulatory
TIDMWDC
RNS Number : 2109V
WideCells Group PLC
26 January 2017
26 January 2017
WideCells Group PLC ('WideCells Group' or 'the Company')
Grant of Options
WideCells Group PLC, the healthcare services company focused on
providing stem cell services and ground breaking insurance for stem
cell treatment, announces that on 24 January 2017 the Company
granted options ("Options") over 600,000 ordinary shares of 0.25
pence each in the capital of the Company ("Ordinary Shares")
pursuant to the Company's EMI Share Option Plan, and 270,290
ordinary shares of 0.25 pence each in the capital of the Company
("Ordinary Shares") pursuant to the Company's 2017 Share Option
Plan For Consultants And Non-Executive Directors. These Options
were granted to Persons Discharging Managerial Responsibilities
("PDMRs") on behalf of the Company.
The 600,000 options for David Bridgland will vest as follows:
200,000 on 27 July 2017, 200,000 on 27 July 2018 and 200,000 on 27
July 2019 subject to continuous employment, except that they will
vest automatically upon the sale of the Company. The 270,290
options for Marilyn Orcharton have been fully vested as a result of
the successful IPO on 27 July 2016 and are subject to her remaining
a non-executive director or consultant to WideCells Group. The
Options are exercisable at 11 pence per Ordinary Share, with an
expiry date for exercise of 27 July 2026.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities / person closely associated
---- ------------------------------------------------------------------
a) Names 1. David Bridgland - Group
CFO
2. Marilyn Orcharton - Non-Executive
Director
---- -------------------------- --------------------------------------
2 Reason for the notification
---- ------------------------------------------------------------------
a) Position/status Directors of the Company
---- -------------------------- --------------------------------------
b) Initial notification Initial Notification
/Amendment
---- -------------------------- --------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---- ------------------------------------------------------------------
a) Name WideCells Group PLC
---- -------------------------- --------------------------------------
b) LEI n/a
---- -------------------------- --------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- ------------------------------------------------------------------
a) Description of The grant of Options on 24
the financial January 2017 over Ordinary
instrument, type Shares
of instrument
---- -------------------------- --------------------------------------
b) Identification GB00BD060S65
code
---- -------------------------- --------------------------------------
c) Nature of the Grant of Options over Ordinary
transaction Shares
---- -------------------------- --------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
--------- ------------
1. 11p 1. 600,000
2. 11p 2. 270,290
--------- ------------
---- -------------------------- --------------------------------------
d) Aggregated information 870,290
- Aggregated volume 11p
- Price
------------------------------- --------------------------------------
e) Date of the transaction 24 January 2017
---- -------------------------- --------------------------------------
f) Place of the transaction Outside a trading venue
---- -------------------------- --------------------------------------
**ENDS**
For further information, please visit the Company's website
www.widecellsgroup.com, follow us on Twitter @WideCells_Group or
contact:
WideCells Group CEO - João Andrade Tel: +351 919
033 171
------------------- ------------------------- --------------
Vicarage Capital Broker - Jeremy Woodgate Tel: +44 (0)
Ltd & Rupert Williams 20 3651 2912
------------------- ------------------------- --------------
Shard Capital Broker - Damon Heath Tel: +44 (0)
Partners LLP & Erik Woolgar 207 186 9950
------------------- ------------------------- --------------
St Brides Partners PR - Elisabeth Cowell Tel: +44 (0)
Ltd & Charlotte Page 20 7236 1177
------------------- ------------------------- --------------
Notes to Editors
WideCells Group PLC is building an integrated stem cell services
company, focused on making stem cell treatments accessible and
affordable. The Directors believe that the use of cord blood stem
cells for transplant will drive one of the next important phases in
medicine and is therefore developing market leading products in
complementary, strategic areas which are designed to take advantage
of substantial market opportunities in one of the fastest growing
segments in the healthcare industry. With this in mind, it has
created three divisions:
-- CellPlan: the world's first stem cell healthcare insurance
plan with financial cover for medical treatment, travel and
accommodation expenses and concierge service to manage the
treatment process
-- WideCells: the Institute of Stem Cell Technology has been
established and is based in the University of Manchester Innovation
Center to focus on stem cell research and regenerative medicine.
WideCells also has international cryogenics divisions specialising
on stem cell storage.
-- WideAcademy: developing an education and training division to
promote awareness of the benefits of stem cell storage across the
global general practice community.
The Group has built an experienced senior management team that
has been integral to the development of its growth and business to
date.
Stem Cell Fast Facts:
-- Cord blood (which is taken from the umbilical cord) provides
the most effective source of stem cells for families due to it
being simple, safe and painless to collect relative to other
sources of stem cells such as bone marrow - WideCells will focus on
promoting the collection and storage of this.
-- Since 2005, there has been a 300% increase in the number of
illnesses that can be treated using stem cells
-- 82 illnesses can currently be treated using stem cell procedures
-- Despite initial storage often costing no more than a few
GBPthousand, actual treatment can cost in the GBPhundreds of
thousands
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014
(MAR).
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBQLFLDFFFBBE
(END) Dow Jones Newswires
January 26, 2017 05:30 ET (10:30 GMT)
Iconic Labs (LSE:ICON)
Historical Stock Chart
From Apr 2024 to May 2024
Iconic Labs (LSE:ICON)
Historical Stock Chart
From May 2023 to May 2024